The Safety, Efficacy, and Cost Effectiveness of Therapeutic Apheresis

July 1983

NTIS order #PB84-114842
Recommended Citation:

Health Technology Case Study 23: The Safety, Efficacy, and Cost Effectiveness of Therapeutic Apheresis (Washington, D. C.: U.S. Congress, Office of Technology Assessment, OTA-HCS-23, June 1983). This case study was performed as a part of OTA’s assessment of Medical Technology and Costs of the Medicare Program.

Library of Congress Catalog Card Number 83-600554

For sale by the Superintendent of Documents,
Preface

The Safety, Efficacy, and Cost Effectiveness of Therapeutic Apheresis is Case Study #23 in OTA’s Health Technology Case Study Series. It was prepared in response to a request by the Senate Finance Committee, Subcommittee on Health, and is part of OTA’s project on Medical Technology and Costs of the Medicare Program, requested by the House Committee on Energy and Commerce and its Subcommittee on Health and the Environment. A listing of other case studies in the series is included at the end of this preface.

OTA case studies are designed to fulfill two functions. The primary purpose is to provide OTA with specific information that can be used in forming general conclusions regarding broader policy issues. The first 19 cases in the Health Technology Case Study Series, for example, were conducted in conjunction with OTA’s overall project on The Implications of Cost-Effectiveness Analysis of Medical Technology. By examining the 19 cases as a group and looking for common problems or strengths in the techniques of cost-effectiveness or cost-benefit analysis, OTA was able to better analyze the potential contribution that those techniques might make to the management of medical technology and health care costs and quality.

The second function of the case studies is to provide useful information on the specific technologies covered. The design and the funding levels of most of the case studies are such that they should be read primarily in the context of the associated overall OTA projects. Nevertheless, in many instances, the case studies do represent extensive reviews of the literature on the efficacy, safety, and costs of the specific technologies and as such can stand on their own as a useful contribution to the field.

Case studies are prepared in some instances because they have been specifically requested by congressional committees and in others because they have been selected through an extensive review process involving OTA staff and consultations with the congressional staffs, advisory panel to the associated overall project, the Health Program Advisory Committee, and other experts in various fields. Selection criteria were developed to ensure that case studies provide the following:

- examples of types of technologies by function (preventive, diagnostic, therapeutic, and rehabilitative);
- examples of types of technologies by physical nature (drugs, devices, and procedures);
- examples of technologies in different stages of development and diffusion (new, emerging, and established);
- examples from different areas of medicine (e.g., general medical practice, pediatrics, radiology, and surgery);
- examples addressing medical problems that are important because of their high frequency or significant impacts (e.g., cost);
- examples of technologies with associated high costs either because of high volume (for low-cost technologies) or high individual costs;
- examples that could provide information material relating to the broader policy and methodological issues being examined in the particular overall project; and
- examples with sufficient scientific literature.

Case studies either are prepared by OTA staff, are commissioned by OTA and performed under contract by experts (generally in academia), or are written by OTA staff on the basis of contractors’ papers.

OTA subjects each case study to an extensive review process. Initial drafts of cases are reviewed by OTA staff and by members of the advisory panel to the associated project. For commissioned cases, “comments are provided to authors, along with OTA’s suggestions for revisions. Subsequent drafts are sent by OTA to numerous experts for review and comment. Each case is seen by at least 30, and sometimes by 80 or more outside reviewers. These reviewers may be from relevant Government agencies, professional societies, consumer and public interest groups, medical practice, and academic medicine. Academicians such as economists, sociologists, decision analysts, biologists, and so forth, as appropriate, also review the cases.

Although cases are not statements of official OTA position, the review process is designed to satisfy OTA of each case study’s scientific quality and objectivity. During the various stages of the review and revision process, therefore, OTA encourages, and to the extent possible requires, authors to present balanced information and recognize divergent points of view.
<table>
<thead>
<tr>
<th>Case Study series number</th>
<th>Case study title; author(s); OTA publication number</th>
<th>Case Study series number</th>
<th>Case study title; author(s); OTA publication number</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Formal Analysis, Policy Formulation, and End-Stage Renal Disease; Richard A. Rettig (OTA-BP-H-9(1))</td>
<td>13</td>
<td>Cardiac Radionuclide Imaging and Cost Effectiveness; William B. Stason and Eric Fortess (OTA-BP-H-9(13))</td>
</tr>
<tr>
<td>3</td>
<td>Screening for Colon Cancer: A Technology Assessment; David M. Eddy (OTA-BP-H-9(3))</td>
<td>15</td>
<td>Elective Hysterectomy: Costs, Risks, and Benefits; Carol Korenbrot, Ann B. Flood, Michael Higgins, Noralou Roos, and John P. Bunker (OTA-BP-H-9(15))</td>
</tr>
<tr>
<td>4</td>
<td>Cost Effectiveness of Automated Multichannel Chemistry Analyzers; Milton C. Weinstein and Laurie A. Pearlman (OTA-BP-H-9(4))</td>
<td>16</td>
<td>The Costs and Effectiveness of Nurse Practitioners; Lauren LeRoy and Sharon Solkowitz (OTA-BP-H-9(16))</td>
</tr>
<tr>
<td>5</td>
<td>Periodontal Disease: Assessing the Effectiveness and Costs of the Keyes Technique; Richard M. Scheffler and Sheldon Rovin (OTA-BP-H-9(5))</td>
<td>17</td>
<td>Surgery for Breast Cancer; Karen Schachter Weingrod and Duncan Neuhauser (OTA-BP-H-9(17))</td>
</tr>
<tr>
<td>6</td>
<td>The Cost Effectiveness of Bone Marrow Transplant Therapy and Its Policy Implications; Stuart O. Schweitzer and C. C. Scalzi (OTA-BP-H-9(6))</td>
<td>18</td>
<td>The Efficacy and Cost Effectiveness of Psychotherapy; Leonard Saxe (Office of Technology Assessment) (OTA-BP-H-9(18))</td>
</tr>
<tr>
<td>7</td>
<td>Allocating Costs and Benefits in Disease Prevention Programs: An Application to Cervical Cancer Screening; Bryan R. Luce (Office of Technology Assessment) (OTA-BP-H-9(7))</td>
<td>19</td>
<td>Assessment of Four Common X-Ray Procedures; Judith L. Wagner (OTA-BP-H-9(19))</td>
</tr>
<tr>
<td>9</td>
<td>The Artificial Heart: Cost, Risks, and Benefits; Deborah P. Lubeck and John P. Bunker (OTA-BP-H-9(9))</td>
<td>21</td>
<td>Selected Telecommunications Devices for Hearing-Impaired Persons; Virginia W. Stern and Martha Ross Redden (OTA-BP-H-16(21))</td>
</tr>
<tr>
<td>10</td>
<td>The Costs and Effectiveness of Neonatal Intensive Care; Peter Budetti, Peggy McManus, Nancy Barrand, and Lu Ann Heinen (OTA-BP-H-9(10))</td>
<td>22</td>
<td>The Effectiveness and Costs of Alcoholism Treatment; Leonard Saxe, Denise Dougherty, Katharine Esty, and Michelle Fine (OTA-CS-H-22)</td>
</tr>
<tr>
<td>11</td>
<td>Benefit and Cost Analysis of Medical Interventions: The Case of Cimetidine and Peptic Ulcer Disease; Harvey V. Fineberg and Laurie A. Pearlman (OTA-BP-H-9(11))</td>
<td>23</td>
<td>The Safety, Efficacy, and Cost Effectiveness of Therapeutic Apheresis; John C. Langenbrunner (Office of Technology Assessment)</td>
</tr>
<tr>
<td>12</td>
<td>Assessing Selected Respiratory Therapy Modalities: Trends and Relative Costs in the Washington, D.C. Area;</td>
<td>24</td>
<td></td>
</tr>
</tbody>
</table>


**Original publication numbers appear in parentheses.**

*The first 17 cases in the series were 17 separately issued Background Paper #2: Case Studies of Medical Technologies, prepared in conjunction with OTA's August 1981 report The Implications of Cost-Effectiveness Analysis of Medical Technology.*
OTA Staff for Case Study #23

H. David Banta, Assistant Director, OTA
Health and Life Sciences Division

Clyde J. Behney, Health Program Manager

John C. Langenbrunner, Study Director

Anne Kesselman Bums, Project Director
Cynthia King, Analyst
Pamela Simerly, Research Assistant
Kerry Britten Kemp, Division Editor

Virginia Cwalina, Administrative Assistant
Jennifer Nelson, Secretary
Mary Walls, Secretary

OTA Publishing Staff

John C. Holmes, Publishing Officer
John Bergling Kathie S. Boss Debra M. Datcher Joe Henson
Glenda Lawing Linda Leahy Donna Young
Advisory Panel on Medical Technology and Costs of the Medicare Program

Stuart Altman, Panel Chair
Dean, Florence Heller School, Brandeis University

Frank Baker
Vice President
Washington State Hospital Association

Robert Blendon
Senior Vice President
The Robert Wood Johnson Foundation

Jerry Cromwell
President
Health Economics Research
Chestnut Hill, Mass.

Karen Davis
Johns Hopkins University
School of Hygiene and Public Health

Robert Derzon
Vice President
Lewin & Associates
Washington, D.C.

Howard Frazier
Director
Center for the Analysis of Health Practices
Harvard School of Public Health

Clifton Gaus
Center for Health Policy Studies
Washington, D.C.

Jack Hadley
Urban Institute
Washington, D.C.

Kate Ireland
Chairman, Board of Governors
Frontier Nursing Service
Wendover, Ky.

Judith Lave
Graduate School of Public Health
University of Pittsburgh

Mary Marshall
filegate
Virginia House of Delegates

Walter McNerney
Northwestern University

Morton Miller
President
National Health Council
New York, N.Y.

James Mongan
Executive Director
Truman Medical Center
Kansas City, Mo.

Seymour Perry
Institute for Health Policy Analysis
Washington, D.C.

Robert Sigmond
Blue Goss of Greater Philadelphia

Anne Somers
Department of Environment and Community and Family Medicine
Rutgers University

Paul Torrens
UCLA School of Public Health

Keith Weikel
Group Vice President
AMI
McLean, Va.